OKYO Pharma Limited

NASDAQ:OKYO

Biotechnology

Healthcare
$1.10 +0.64%

+$0.01 today

Market cap
$57.73M
Beta
0.02
P/E (TTM)
-12.8
EPS (TTM)
-$0.12
52W Low $1.42High $3.35

Volume 0.24M

Average 0.07M

OKYO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

OKYO Pharma LimitedNASDAQ: OKYO

Research & Development · Q2 FY2026 · quarter ended Sep 2025

Research & development turns negative

Q2 FY2026 research & development was -$44.05K, compared with $2.22M a year earlier. Over 3 fiscal years it compounded at +11.9% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2025
-$44.05K— QoQ
Last fiscal yearMar 2025
$2.25M-72.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-102.0%——
1 year-72.7%——
3-year CAGR+11.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
2.25M USD
Year-over-year change
-72.7%
4-year CAGR
+59.5%

Research & Development vs competitors

How OKYO compares with its peers on the latest reported figures

  • OKYO's FY2025 research & development of $2.25M is the lowest of the 10 companies compared; the peer median is $79.04M.
  • Its year-over-year change of -72.7% is the lowest of 10, against a peer median of -17.9%.
  • Over three fiscal years its annual growth of +11.9% compares with a peer median of +4.0%.
OKYO Competitors Peer median
Research & Development for OKYO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COYACoya Therapeutics, Inc.LTM Mar 2026$3.68B +26273.1%+50.2%46313.4%
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M -19.9%-12.2%86.2%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$108.76M -25.2%-14.7%—
WHWKWhitehawk Therapeutics IncLTM Mar 2026$99.41M +115.1%+40.7%—
PLRXPliant Therapeutics, Inc.LTM Mar 2026$79.04M -54.8%+4.0%—
IMMXImmix Biopharma, Inc.LTM Mar 2026$20.26M +102.3%+57.1%—
SLGLSol-Gel Technologies Ltd.LTM Mar 2026$16.75M -21.4%+21.6%90.7%
CLNNClene Inc.LTM Mar 2026$12.86M -17.9%-24.0%9596.3%
TLSATiziana Life Sciences LtdFY2025$10.28M +96.6%-13.6%—
OKYOOKYO Pharma LimitedFY2025$2.25M -72.7%+11.9%—
Peer median (excluding OKYO) $79.04M-17.9%+4.0%4843.5%

Competitors are the stored peer set for OKYO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Mar 2021
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
Revenue00000
Cost of Revenue13.09K2.42K3.8K3.87K2.56K
Gross Profit(13.09K)(2.42K)(3.8K)(3.87K)(2.56K)
Gross Margin—————
Research & Development348.35K1.61M6.34M8.24M2.25M
Selling, General & Admin2.97M4.93M6.75M7.45M4.93M
Operating Expenses3.37M6.22M6.34M15.69M7.19M
Depreciation & Amortization13.11K2.33K3.8K3.87K2.56K
EBITDA(3.35M)(6.22M)(13.18M)(15.75M)(7.08M)
EBITDA Margin—————
Operating Income(4.13M)(6.23M)(13.09M)(15.69M)(7.19M)
Operating Margin—————
Interest Income00005.47K
Interest Expense1.12K096.69K1.05M883.65K
Other Income / Expenses754.85K13.58K(196.62K)(1.11M)(781.2K)
Income Before Tax(3.38M)(6.22M)(13.28M)(16.8M)(7.97M)
Pre-Tax Margin—————
Income Tax Expense(24.99K)(787K)(12.2K)22.42K(3.26M)
Net Income(3.35M)(5.43M)(13.27M)(16.83M)(4.71M)
Net Margin—————
EPS (Basic)(0.32)(0.36)(0.60)(0.00)(0.12)
EPS (Diluted)(0.32)(0.36)(0.60)(0.00)(0.12)
Weighted Avg Shares10.35M15.06M22.26M29.34M39.49M
Weighted Avg Shares (Diluted)10.35M15.06M22.26M29.34M39.49M

OKYO Pharma Limited

NASDAQ:OKYO

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.